Of the 7 suppliers of COVID-19 vaccines across Canada, only 2 have manufacturing sites in Canada. Details on Canada’s approach to sourcing and manufacturing for COVID-19 vaccines have been presented below.
Canada’s Approach to Sourcing and Manufacturing for COVID-19 Vaccines
- Canada runs an intergovernmental procurement system, the federal, provincial, and territorial governments of Canada work together to provide “equitable access to publicly funded pandemic vaccines for COVID-19.”
- On December 9, 2020, Health Canada approved Pfizer-BioNTech mRNA vaccine. Health Canada also approved Moderna mRNA vaccine on December 23, 2020.
- Canada has negotiated 358 million doses for 179 million people (7 different suppliers, 2 of which are manufactured in Canada.)
- These suppliers include Pfizer-BioNTech, Moderna, Sanofi and GSK, Medicago, AstraZeneca, Johnson & Johnson, and Novavax. Of these 7 suppliers, only Sanofi and GSK, and Medicago have manufacturing sites in Canada.
- Of the 7 suppliers, Pfizer-BioNTech and Moderna have been given Health Canada approval, AstraZeneca, and Johnson & Johnson are under Health Canada review. On the other hand, Sanofi and GSK, Medicago, and Novavax are not yet under Health Canada review.
- “The Government of Canada will also provide additional support for securing storage facilities, getting supplies (like needles, swabs and gauze), and helping with distribution across the country.”
Insights on Canada’s COVID-19 Vaccine sourcing and manufacturing
Negotiating the Purchase of Locally Manufactured Vaccines
- Negotiating the purchase of 148 million doses from Sanofi and GSK, and Medicago, companies that have local COVID-19 manufacturing sites in Canada, will enable quick distributions of these vaccines once approved.
Slow Supply of Vaccine Negotiated
- Of the 20 million Pfizer-BioNTech vaccine doses negotiated (approved Dec 9th, 2020), only 249,000 doses had been delivered on January 6th. This level of efficiency could be considered very poor in comparison to other first world countries.